

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



中國光大控股有限公司
CHINA EVERBRIGHT LIMITED
(Incorporated in Hong Kong with limited liability)
(Stock Code: 165)

CHANGE OF EXECUTIVE DIRECTOR AND VICE PRESIDENT AND COMPOSITION OF BOARD COMMITTEES

Resignation of an Executive Director

The board (the “**Board**”) of directors (the “**Director(s)**”) of China Everbright Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Mr. Yin Yanwu (“**Mr. Yin**”) has resigned as an Executive Director and the Vice President of the Group and a member of the Executive Board Committee of the Board due to work arrangement with effect from 18 December 2025.

Mr. Yin has confirmed that he has no disagreement with the Board and there are no matters with respect to his resignation that needs to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Mr. Yin has demonstrated dedication and diligence during his tenure as an Executive Director and the Vice President of the Group. The Board would like to express its gratitude to Mr. Yin for his contributions to the Group.

Appointment of an Executive Director

The Board announces that with effect from 18 December 2025, Dr. Su Yang (“**Dr. Su**”) has been appointed as an Executive Director and the Vice President of the Group, and a member of the Executive Board Committee of the Board. The biographical details of Dr. Su are set out below:

Dr. Su Yang, aged 44, is an Executive Director and Vice President of the Group in charge of the Real Estate Fund Investment and Management Centre and the Medical and Related Business Fund Department. He is also a member of the Executive Board Committee of the Board and the Management Decision Committee of the Group. Dr. Su worked at China Everbright Bank Company Limited (stock code: 601818.SH, 6818.HK) in July 2000, successively in the Audit Department, General Office and Investment Banking Department. Dr. Su joined Sun Life Everbright Life Insurance Co., Ltd. in March 2013, served as Board Secretary in May 2013, concurrently served as Director of the Board Office and Director of the Supervisory Board Office in December 2013, served as Assistant General Manager in January 2018, and served as the Deputy General Manager in August 2019. He has served as a Director of China Everbright Senior Healthcare Company Limited and a Director of Everbright Senior Healthcare Company Limited* (光大養老健康產業發展有限公司) since November 2022. Dr. Su holds a Bachelor's Degree in industrial foreign trade from Shanghai Jiao Tong University, a Master's Degree in economics from Peking University, and a Doctor's Degree in economics from Southwestern University of Finance and Economics.

Save as disclosed above, Dr. Su (i) does not hold and has not held any other directorships in the last three years in any other public companies, the securities of which are listed on any securities market in Hong Kong or overseas; (ii) does not hold any other position in the Group; and (iii) does not have any other relationship with the Directors, senior management and substantial or controlling shareholders of the Company.

As at the date of this announcement, Dr. Su does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong. Dr. Su has entered into a service contract with the Company with no specific term and Dr. Su is subject to retirement by rotation and re-election at annual general meetings in accordance with the articles of association of the Company.

There is no director's emolument and salary for Dr. Su as an Executive Director. For his employment as the Vice President of the Group, Dr. Su is entitled to a salary of HK\$1,440,100 per annum and is also entitled to a discretionary bonus. Dr. Su's remuneration is determined by the Remuneration Committee of the Board with reference to his duties and responsibilities, the performance of the Company and the market conditions.

Save as disclosed above, the Board is not aware of any other matters or information in relation to the appointment of Dr. Su that need to be brought to the attention of the shareholders of the Company or to be disclosed pursuant to Rule 13.51(2) of the Listing Rules.

The Board would like to express its welcome to Dr. Su for joining the Board.

By Order of the Board
China Everbright Limited
Wan Kim Ying Kasina
Company Secretary

Hong Kong, 18 December 2025

As at the date of this announcement, the directors of the Company are:

Executive Directors:

Mr. Lin Chun (*President*)
Mr. Pan Jianyun
Mr. An Xuesong
Dr. Su Yang

Non-executive Directors:

Mr. Yu Fachang (*Chairman*)
Dr. Qin Hongyuan

Independent Non-executive Directors:

Dr. Lin Zhijun
Mr. Law Cheuk Kin Stephen
Mr. Wong Chun Sek Edmund
Dr. Young Danqing Xu

** For identification purposes only*